What is Globus Medical?
, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
GMED · Verdict
Strong reward · low risk
GMED scores well on balance sheet and profitability with no major weaknesses flagged in the model.
Based on 88% data coverage
GMED · Verdict
Current ratio 4.26
18% net margin · 10% ROE
Rev +42.2% CAGR · earnings +41.4%
20% free-cash-flow margin
P/E 15.8× · PEG 1.73
Model-based scoring. For information only — not financial advice.
, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 13.00B, and a P/E ratio of 31.1x.
The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.